HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment

Claudia Colussi, Chiara Mozzetta, Aymone Gurtner, Barbara Illi, Jessica Rosati, Stefania Straino, Gianluca Ragone, Mario Pescatori, Germana Zaccagnini, Annalisa Antonini, Giulia Minetti, Fabio Martelli, Giulia Piaggio, Paola Gallinari, Christian Steinkulher, Emilio Clementi, Carmela Dell'Aversana, Lucia Altucci, Antonello Mai, Maurizio C. CapogrossiPier Lorenzo Puri, Carlo Gaetano

Research output: Contribution to journalArticle

Abstract

The overlapping histological and biochemical features underlying the beneficial effect of deacetylase inhibitors and NO donors in dystrophic muscles suggest an unanticipated molecular link among dystrophin, NO signaling, and the histone deacetylases (HDACs). Higher global deacetylase activity and selective increased expression of the class I histone deacetylase HDAC2 were detected in muscles of dystrophin-deficient MDX mice. In vitro and in vivo siRNA-mediated down-regulation of HDAC2 in dystrophic muscles was sufficient to replicate the morphological and functional benefits observed with deacetylase inhibitors and NO donors. We found that restoration of NO signaling in vivo, by adenoviral-mediated expression of a constitutively active endothelial NOS mutant in MDX muscles, and in vitro, by exposing MDX-derived satellite cells to NO donors, resulted in HDAC2 blockade by cysteine S-nitrosylation. These data reveal a special contribution of HDAC2 in the pathogenesis of Duchenne muscular dystrophy and indicate that HDAC2 inhibition by NO-dependent S-nitrosylation is important for the therapeutic response to NO donors in MDX mice. They also define a common target for independent pharmacological interventions in the treatment of Duchenne muscular dystrophy.

Original languageEnglish
Pages (from-to)19183-19187
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume105
Issue number49
DOIs
Publication statusPublished - Dec 9 2008

Fingerprint

Histone Deacetylase Inhibitors
Duchenne Muscular Dystrophy
Nitric Oxide
Muscles
Dystrophin
Histone Deacetylase 2
Histone Deacetylases
Small Interfering RNA
Cysteine
Down-Regulation
Pharmacology
In Vitro Techniques
Therapeutics

Keywords

  • Epigenetic
  • Skeletal muscle

ASJC Scopus subject areas

  • General

Cite this

HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. / Colussi, Claudia; Mozzetta, Chiara; Gurtner, Aymone; Illi, Barbara; Rosati, Jessica; Straino, Stefania; Ragone, Gianluca; Pescatori, Mario; Zaccagnini, Germana; Antonini, Annalisa; Minetti, Giulia; Martelli, Fabio; Piaggio, Giulia; Gallinari, Paola; Steinkulher, Christian; Clementi, Emilio; Dell'Aversana, Carmela; Altucci, Lucia; Mai, Antonello; Capogrossi, Maurizio C.; Puri, Pier Lorenzo; Gaetano, Carlo.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 105, No. 49, 09.12.2008, p. 19183-19187.

Research output: Contribution to journalArticle

Colussi, C, Mozzetta, C, Gurtner, A, Illi, B, Rosati, J, Straino, S, Ragone, G, Pescatori, M, Zaccagnini, G, Antonini, A, Minetti, G, Martelli, F, Piaggio, G, Gallinari, P, Steinkulher, C, Clementi, E, Dell'Aversana, C, Altucci, L, Mai, A, Capogrossi, MC, Puri, PL & Gaetano, C 2008, 'HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment', Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 49, pp. 19183-19187. https://doi.org/10.1073/pnas.0805514105
Colussi, Claudia ; Mozzetta, Chiara ; Gurtner, Aymone ; Illi, Barbara ; Rosati, Jessica ; Straino, Stefania ; Ragone, Gianluca ; Pescatori, Mario ; Zaccagnini, Germana ; Antonini, Annalisa ; Minetti, Giulia ; Martelli, Fabio ; Piaggio, Giulia ; Gallinari, Paola ; Steinkulher, Christian ; Clementi, Emilio ; Dell'Aversana, Carmela ; Altucci, Lucia ; Mai, Antonello ; Capogrossi, Maurizio C. ; Puri, Pier Lorenzo ; Gaetano, Carlo. / HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. In: Proceedings of the National Academy of Sciences of the United States of America. 2008 ; Vol. 105, No. 49. pp. 19183-19187.
@article{3fd22fd749924efebb1b97643bc035d1,
title = "HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment",
abstract = "The overlapping histological and biochemical features underlying the beneficial effect of deacetylase inhibitors and NO donors in dystrophic muscles suggest an unanticipated molecular link among dystrophin, NO signaling, and the histone deacetylases (HDACs). Higher global deacetylase activity and selective increased expression of the class I histone deacetylase HDAC2 were detected in muscles of dystrophin-deficient MDX mice. In vitro and in vivo siRNA-mediated down-regulation of HDAC2 in dystrophic muscles was sufficient to replicate the morphological and functional benefits observed with deacetylase inhibitors and NO donors. We found that restoration of NO signaling in vivo, by adenoviral-mediated expression of a constitutively active endothelial NOS mutant in MDX muscles, and in vitro, by exposing MDX-derived satellite cells to NO donors, resulted in HDAC2 blockade by cysteine S-nitrosylation. These data reveal a special contribution of HDAC2 in the pathogenesis of Duchenne muscular dystrophy and indicate that HDAC2 inhibition by NO-dependent S-nitrosylation is important for the therapeutic response to NO donors in MDX mice. They also define a common target for independent pharmacological interventions in the treatment of Duchenne muscular dystrophy.",
keywords = "Epigenetic, Skeletal muscle",
author = "Claudia Colussi and Chiara Mozzetta and Aymone Gurtner and Barbara Illi and Jessica Rosati and Stefania Straino and Gianluca Ragone and Mario Pescatori and Germana Zaccagnini and Annalisa Antonini and Giulia Minetti and Fabio Martelli and Giulia Piaggio and Paola Gallinari and Christian Steinkulher and Emilio Clementi and Carmela Dell'Aversana and Lucia Altucci and Antonello Mai and Capogrossi, {Maurizio C.} and Puri, {Pier Lorenzo} and Carlo Gaetano",
year = "2008",
month = "12",
day = "9",
doi = "10.1073/pnas.0805514105",
language = "English",
volume = "105",
pages = "19183--19187",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "49",

}

TY - JOUR

T1 - HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment

AU - Colussi, Claudia

AU - Mozzetta, Chiara

AU - Gurtner, Aymone

AU - Illi, Barbara

AU - Rosati, Jessica

AU - Straino, Stefania

AU - Ragone, Gianluca

AU - Pescatori, Mario

AU - Zaccagnini, Germana

AU - Antonini, Annalisa

AU - Minetti, Giulia

AU - Martelli, Fabio

AU - Piaggio, Giulia

AU - Gallinari, Paola

AU - Steinkulher, Christian

AU - Clementi, Emilio

AU - Dell'Aversana, Carmela

AU - Altucci, Lucia

AU - Mai, Antonello

AU - Capogrossi, Maurizio C.

AU - Puri, Pier Lorenzo

AU - Gaetano, Carlo

PY - 2008/12/9

Y1 - 2008/12/9

N2 - The overlapping histological and biochemical features underlying the beneficial effect of deacetylase inhibitors and NO donors in dystrophic muscles suggest an unanticipated molecular link among dystrophin, NO signaling, and the histone deacetylases (HDACs). Higher global deacetylase activity and selective increased expression of the class I histone deacetylase HDAC2 were detected in muscles of dystrophin-deficient MDX mice. In vitro and in vivo siRNA-mediated down-regulation of HDAC2 in dystrophic muscles was sufficient to replicate the morphological and functional benefits observed with deacetylase inhibitors and NO donors. We found that restoration of NO signaling in vivo, by adenoviral-mediated expression of a constitutively active endothelial NOS mutant in MDX muscles, and in vitro, by exposing MDX-derived satellite cells to NO donors, resulted in HDAC2 blockade by cysteine S-nitrosylation. These data reveal a special contribution of HDAC2 in the pathogenesis of Duchenne muscular dystrophy and indicate that HDAC2 inhibition by NO-dependent S-nitrosylation is important for the therapeutic response to NO donors in MDX mice. They also define a common target for independent pharmacological interventions in the treatment of Duchenne muscular dystrophy.

AB - The overlapping histological and biochemical features underlying the beneficial effect of deacetylase inhibitors and NO donors in dystrophic muscles suggest an unanticipated molecular link among dystrophin, NO signaling, and the histone deacetylases (HDACs). Higher global deacetylase activity and selective increased expression of the class I histone deacetylase HDAC2 were detected in muscles of dystrophin-deficient MDX mice. In vitro and in vivo siRNA-mediated down-regulation of HDAC2 in dystrophic muscles was sufficient to replicate the morphological and functional benefits observed with deacetylase inhibitors and NO donors. We found that restoration of NO signaling in vivo, by adenoviral-mediated expression of a constitutively active endothelial NOS mutant in MDX muscles, and in vitro, by exposing MDX-derived satellite cells to NO donors, resulted in HDAC2 blockade by cysteine S-nitrosylation. These data reveal a special contribution of HDAC2 in the pathogenesis of Duchenne muscular dystrophy and indicate that HDAC2 inhibition by NO-dependent S-nitrosylation is important for the therapeutic response to NO donors in MDX mice. They also define a common target for independent pharmacological interventions in the treatment of Duchenne muscular dystrophy.

KW - Epigenetic

KW - Skeletal muscle

UR - http://www.scopus.com/inward/record.url?scp=58049221125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58049221125&partnerID=8YFLogxK

U2 - 10.1073/pnas.0805514105

DO - 10.1073/pnas.0805514105

M3 - Article

C2 - 19047631

AN - SCOPUS:58049221125

VL - 105

SP - 19183

EP - 19187

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 49

ER -